Evidence map›Paper›PMID 42387291›Full record

ReviewClinical and experimental immunology2026

The many faces of cytokine storm syndrome: immunopathogenic mechanisms and clinical implications for a better patient management.

Piero Ruscitti

Abstract readReview
In one paragraph

Review in Clinical and experimental immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Piero RuscittiDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.ORCID 0000-0003-3487-8551

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytokine storm syndrome is a life-threatening hyperinflammatory condition characterized by excessive and dysregulated immune activation, leading to multiorgan dysfunction and poor clinical outcomes if not promptly recognized and adequately treated. Rather than representing a single disease entity, cytokine storm syndrome is increasingly understood as a final common pathogenic pathway shared by a broad spectrum of clinical conditions converging on overlapping immunopathological mechanisms driven by sustained cytokine production, immune-cell hyperactivation, and failure of immune-regulatory pathways. The clinical presentation of cytokine storm syndrome is characterized by a rapidly progressive nature, multisystem involvement, and the diagnostic challenges arising from nonspecific symptoms and overlapping laboratory features. Hyperferritinaemia emerges as a central laboratory hallmark with both diagnostic and potential pathogenic relevance. Therapeutic management of cytokine storm syndrome requires early recognition and is guided by three core principles: supportive care for organ dysfunction, control of underlying triggers, and timely immunomodulatory or immunosuppressive interventions. Overall, cytokine storm syndrome represents a complex and heterogeneous clinical syndrome in which improved mechanistic understanding, biomarker development, and tailored therapeutic strategies are essential to optimize patient outcomes.

Indexed as

Cytokine Release SyndromeAnimalsBiomarkersCytokinesDisease ManagementHumansMultiple Organ FailureBiomarkersCytokinescytokine storm syndromehyperferritinemiainflammationprognosis

Identifiers

PMID42387291
PMCPMC13378767

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.